# Cardinal Health, Inc. (CAH) Stock Analysis: Insights on a 15.5% Potential Upside and Strong Buy Ratings

- Link: https://www.directorstalkinterviews.com/cardinal-health-inc-cah-stock-analysis-insights-on-a-15-5-potential-upside-and-strong-buy-ratings/4121262359
- Published: 2026-09-14T10:17:11+01:00
- Author: Madison Wilson

Cardinal Health, Inc. (NYSE: CAH) stands out in the healthcare sector with a robust
profile as a medical distribution giant. Headquartered in Dublin, Ohio, this company
plays a pivotal role in the global healthcare supply chain. Specializing in pharmaceutical
and specialty solutions, as well as global medical products and distribution, Cardinal
Health is a key player in delivering vital medical supplies and services across 
the healthcare landscape.

For investors, Cardinal Health presents a compelling opportunity, particularly with
a market capitalization of $54.56 billion. The current stock price hovers around
$234.57, reflecting a slight dip of 0.01% from previous levels. Despite this minor
fluctuation, the stock maintains a stable position against its 52-week range of 
$147.47 to $248.61, demonstrating resilience and growth potential.

A highlight for potential investors is the company’s anticipated forward P/E ratio
of 16.66, which suggests a reasonable valuation relative to future earnings expectations.
The lack of a trailing P/E and other valuation metrics, such as the PEG ratio and
price-to-sales, might raise eyebrows; however, these gaps can often be attributed
to atypical accounting situations or recent financial adjustments.

Cardinal Health has demonstrated solid revenue growth of 5.80%, supported by an 
earnings per share (EPS) of 7.22. While net income and return on equity figures 
are not disclosed, the reported free cash flow of over $4.75 billion underscores
significant financial flexibility, which is crucial for both ongoing operations 
and strategic investments.

From a dividend perspective, Cardinal Health offers a yield of 0.88% with a conservative
payout ratio of 28.33%. This indicates a prudent approach to returning capital to
shareholders while ensuring sufficient reinvestment in growth opportunities.

Analyst sentiment is notably positive, with 15 buy ratings, 3 hold ratings, and 
no sell ratings, underscoring confidence in the company’s trajectory. The average
target price of $270.94 suggests a potential upside of 15.50%, providing an attractive
proposition for growth-focused investors.

Technical indicators also paint an encouraging picture. The current price aligns
closely with the 50-day moving average of $234.26, with a comfortable margin above
the 200-day moving average of $216.35. The Relative Strength Index (RSI) of 56.46
indicates a neutral market sentiment, while the MACD and signal line values suggest
a positive momentum trend.

Cardinal Health’s comprehensive suite of services—from pharmaceutical distribution
to medical product manufacturing—positions it well for continued success. The company’s
ability to offer customized solutions across diverse healthcare settings, combined
with its strategic global presence, underpins its competitive edge in the industry.

For investors seeking a blend of stability and growth potential within the healthcare
sector, Cardinal Health represents a solid choice. With strong analyst support, 
a promising upside potential, and a robust operational framework, Cardinal Health
is poised to maintain its critical role in the healthcare supply chain while delivering
shareholder value.

Share on:
